SCHEMBL6133092

SCHEMBL6133092

Cn1nccc1CCNC(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
GFER P55789 1/20 0.48
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TDP1 Q9NUW8 2/20 0.43
MAPT P10636 1/20 0.43
NQO2 P16083 1/20 0.43
LMNA P02545 3/20 0.42
NAMPT P43490 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
PCSK9 Q8NBP7 1/20 0.41
DRD2 P14416 2/20 0.41
TSHR P16473 2/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.41
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18878008 0.86 L3MBTL1 (0.58) GFERKMT2AL3MBTL1LMNANAMPT
SCHEMBL26926861 0.80 CA12 (0.50) ALDH1A1GFERPCSK9DRD2
SCHEMBL25056365 0.76 KMT2A (0.44) ALDH1A1KMT2AL3MBTL1TDP1MAPT
SCHEMBL1630312 0.75 MAPK1 (0.50) ALDH1A1GFERHTTNPSR1TDP1
SCHEMBL23384726 0.75 KMT2A (0.46) ALDH1A1HTTKMT2AL3MBTL1LMNA
SCHEMBL28560594 0.75 ALDH1A1 (0.48) ALDH1A1GFERHTTNPSR1KMT2A
SCHEMBL1630309 0.74 DRD2 (0.43) ALDH1A1GFERHTTNPSR1TDP1
SCHEMBL25056345 0.74 KMT2A (0.39) KMT2AL3MBTL1
SCHEMBL23028534 0.74 DRD2 (0.48) DRD2PKM
SCHEMBL2024124 0.74 CYP17A1 (0.53) ALDH1A1GFERHTTNPSR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192734-A1 TRICYCLIC COMPOUNDS AS EGFR INHIBITORS QILU PHARMACEUTICAL CO LTD (CN) 2023-06-22 US disclosed
US-20230192734-A1 TRICYCLIC COMPOUNDS AS EGFR INHIBITORS QILU PHARMACEUTICAL CO LTD (CN) 2023-06-22 US disclosed
EP-4137484-A1 TRICYCLIC COMPOUNDS AS EGFR INHIBITORS QILU PHARMACEUTICAL CO., LTD. (CN) 2023-02-22 EP disclosed
US-20050004094-A1 Cephem compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-06 US disclosed
WO-2004101571-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004094-A1 Cephem compounds CEP170, C1S, CEPT1 ALDH1A1 2105/4885GFER 1394/4885HTT 1106/4885
US-20230192734-A1 TRICYCLIC COMPOUNDS AS EGFR INHIBITORS EGFR, ERBB2, ERBB3 ALDH1A1 3656/4885GFER 4730/4885HTT 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.